The benefits of continuous epidural infusion of ropivacaine in acute pancreatitis

Not Applicable

• Conditions: Severe and predicted severe acute pancreatitis; Digestive System

• Registration Number: ISRCTN82550530
• Lead Sponsor: B?ch Mai Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-09-29
• Last Update Posted: 30 October 2023
• Study Completion: 2025-12-09

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

1. Aged = 18 years.
2. Diagnosis of acute pancreatitis required two of the following three features, as per the revised Atlanta definition: abdominal pain consistent with acute pancreatitis, serum lipase activity at least three times greater than the upper limit of normal, and characteristic findings of acute pancreatitis on contrast-enhanced computed tomography.
3. Onset = 72 h.
4. Pain moderate or severe with visual analog pain scale (VAS) = 4 in consciousness patients or behavioral pain scale (BPS) = 7 in unconsciousness patients.
5. Classification is severe acute pancreatitis (modified Marshall score = 2 on admission) OR predicted severe (at least one of criteria: (1) Ranson's Criteria = 2 points; (2) CRP level > 100 mg/L; (3) Pancreatic necrosis on contrast-enhanced computed tomography.

Exclusion Criteria

Patients fulfilling one or more of the following criteria were not included:
1. Prothrombin time < 60%, platelet count < 75 G/L, curative anticoagulant therapy with heparin interrupted for less than 8 h
2. Local infection
3. Failed procedure
4. Anaphylaxis history with ropivacaine, lidocaine, ropivacaine
5. Local anesthetic systemic toxicity history
6. Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified